Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 3/2014

01.07.2014 | Evidence-Based Review

Androgenetic Alopecia: An Evidence-Based Treatment Update

verfasst von: Supenya Varothai, Wilma F. Bergfeld

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Androgenetic alopecia (AGA) is one of the most common chronic problems seen by dermatologists worldwide. It is characterized by progressive hair loss, especially of scalp hair, and has distinctive patterns of loss in women versus men, but in both genders the central scalp is most severely affected. It often begins around puberty and is known to effect self-esteem and the individual’s quality of life. In contrast to the high prevalence of AGA, approved therapeutic options are limited. In addition to the scarce pharmacologic treatments, there are numerous nonprescription products claimed to be effective in restoring hair in androgenetic alopecia.

Objectives

The purpose of this paper is to review published medical and non-medical treatments for male and female AGA using the American College of Physicians evidence assessment methods. MEDLINE, EMBASE and Cochrane Library were searched for systematic reviews, randomized controlled trials, open studies, case reports and relevant studies of the treatment of male and female AGA. The relevant articles were classified according to grade and level of evidence.

Results

The medical treatments with the best level of evidence classification for efficacy and safety for male AGA are oral finasteride and topical minoxidil solution. For female AGA, topical minoxidil solution appears to be the most effective and safe treatment. The medical treatments corresponding to the next level of evidence quality are some commonly used therapeutic non-FDA-approved options including oral and topical anti-hormonal treatments. Surgical treatment of follicular unit hair transplantation is an option in cases that have failed medical treatment although there is high variation in outcomes.

Limitations

Some articles, especially those concerning traditional herbs claimed to promote hair regrowth, were published in non-English, local journals.

Conclusions

An assessment of the evidence quality of current publications indicates that oral finasteride (for men only) and topical minoxidil (for men and women) are the best treatments of AGA.
Literatur
1.
Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53:708–28.PubMedCrossRef
2.
Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10:184–9.PubMedCrossRef
3.
Han SH, Byun JW, Lee WS, et al. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol. 2012;24:311–8.PubMedCentralPubMedCrossRef
4.
Qaseem A, Snow V, Owens DK, Shekelle P. Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med. 2010;153:194–9.PubMedCrossRef
5.
Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146:1141–50.PubMedCrossRef
6.
Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9(Suppl 6):S1–57.PubMedCrossRef
7.
Bergstrom KG. What’s new in androgenetic alopecia: approvals, long-term safety data, cancer risk and treatment options for women. J Drugs Dermatol. 2011;10:98–101.PubMed
8.
Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8:1747–53.PubMedCrossRef
9.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8:872–84.PubMedCrossRef
10.
Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9:2927–32.PubMedCrossRef
11.
Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73:1220–3.PubMedCrossRef
12.
Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction? Dermatol Ther. 2010;23:544–6.PubMedCrossRef
13.
D’Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007;8:21–5.PubMedCrossRef
14.
Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010;11:1295–304.PubMedCrossRef
15.
Shenoy NK, Prabhakar SM. Finasteride and male breast cancer: does the MHRA report show a link? J Cutan Aesthet Surg. 2010;3:102–5.PubMedCentralPubMed
16.
Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M. Male breast cancer and 5alpha-reductase inhibitors finasteride and dutasteride. J Urol. 2013;190:1811–4.PubMedCrossRef
17.
Atanaskova Mesinkovska N, Bergfeld WF. Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. Dermatol Clin. 2013;31:119–27.PubMed
18.
Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43:768–76.PubMedCrossRef
19.
Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999;4:282–4.PubMedCrossRef
20.
Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142:298–302.PubMedCrossRef
21.
Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol. 2002;47:733–9.PubMedCrossRef
22.
Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003;74:393–406.PubMedCrossRef
23.
Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55:1014–23.PubMedCrossRef
24.
Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63:252–8.PubMedCrossRef
25.
Gupta AK, Charrette A. The efficacy and safety of 5alpha-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatol Treat. 2014;25(2):156–61.
26.
Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75:47–51.PubMedCrossRef
27.
Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4:637–40.PubMed
28.
Moftah N, Moftah N, Abd-Elaziz G, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27:686–93.PubMedCrossRef
29.
Patel MPA, Sinclair R. An overview of female pattern hair loss. Expert Rev Dermatol. 2011;6:311–27.CrossRef
30.
van Zuuren EJ, Fedorowicz Z, Carter B. Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. Br J Dermatol. 2012;167:995–1010.PubMedCrossRef
31.
Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152:466–73.PubMedCrossRef
32.
Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol. 1989;69:395–8.PubMed
33.
Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011;45:469–75.PubMedCrossRef
34.
Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79:91–5.PubMedCrossRef
35.
Yazdabadi A, Sinclair R. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Aust J Dermatol. 2011;52:132–4.CrossRef
36.
Adenuga P, Summers P, Bergfeld W. Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy. J Am Acad Dermatol. 2012;67:e121–3.PubMedCrossRef
37.
Blume-Peytavi U, Kunte C, Krisp A, Garcia Bartels N, Ellwanger U, Hoffmann R. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges. 2007;5:391–5.PubMedCrossRef
38.
Wozel GNS, Jackel A, Lutz GA. An effective and safe therapy for the treatment of androgenetic alopecia in women and men. Aktuel Dermatol. 2005;31:553–60.CrossRef
39.
Sovak M, Seligson AL, Kucerova R, Bienova M, Hajduch M, Bucek M. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience. Dermatol Surg. 2002;28:678–85.PubMed
40.
Kucerova R, Bienova M, Novotny R. Current therapies of female androgenetic alopecia and use of fluridil, a novel topical antiandrogen. Scr Med (Brno). 2006;79:35–48.
41.
Ohnemus U, Unalan M, Handjiski B, Paus R. Topical estrogen accelerates hair regrowth in mice after chemotherapy-induced alopecia by favoring the dystrophic catagen response pathway to damage. J Investig Dermatol. 2004;122:7–13.PubMedCrossRef
42.
Gassmueller J, Hoffmann R, Webster A. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. Br J Dermatol. 2008;158:109–15.PubMed
43.
Goh C, Zippin JH. Androgenetic alopecia: diagnosis and treatment with a focus on recent genetic implications. J Drugs Dermatol. 2009;8:185–92.PubMed
44.
Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6:130–6.PubMedCrossRef
45.
Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs. 2013;22:573–89.PubMedCrossRef
46.
van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2012;5:CD007628.PubMed
47.
Tsuboi R, Arano O, Nishikawa T, Yamada H, Katsuoka K. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. J Dermatol. 2009;36:437–46.PubMedCrossRef
48.
Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29:489–98.PubMed
49.
Berger RS, Fu JL, Smiles KA, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003;149:354–62.PubMedCrossRef
50.
Bazzano GS, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol. 1986;15:880–3, 90–3.
51.
Shin HS, Won CH, Lee SH, Kwon OS, Kim KH, Eun HC. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am J Clin Dermatol. 2007;8:285–90.PubMedCrossRef
52.
Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol. 2002;146:992–9.PubMedCrossRef
53.
Pazoki-Toroudi H, Babakoohi S, Nilforoushzadeh MA, et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed. 2012;10:276–82.PubMed
54.
Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57:767–74.PubMedCrossRef
55.
Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermat. 2011;65:1126–34 e2.
56.
Banka N, Bunagan MJ, Shapiro J. Pattern hair loss in men: diagnosis and medical treatment. Dermatol Clin. 2013;31:129–40.PubMed
57.
American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93:137–50.
58.
Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4:126ra34.PubMedCentralPubMedCrossRef
59.
Blume-Peytavi U, Lonnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66:794–800.PubMedCrossRef
60.
Emer JJ, Stevenson ML, Markowitz O. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution. J Drugs Dermatol. 2011;10:795–8.PubMed
61.
Olsen EA, DeLong E. Transdermal viprostol in the treatment of male pattern baldness. J Am Acad Dermatol. 1990;23:470–2.PubMedCrossRef
62.
Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses. 2004;62:112–5.PubMedCrossRef
63.
Inui S, Itami S. Reversal of androgenetic alopecia by topical ketoconzole: relevance of anti-androgenic activity. J Dermatol Sci. 2007;45:66–8.PubMedCrossRef
64.
Sonino N, Scaroni C, Biason A, Boscaro M, Mantero F. Low-dose ketoconazole treatment in hirsute women. J Endocrinol Investig. 1990;13:35–40.CrossRef
65.
Fischer TW, Slominski A, Tobin DJ, Paus R. Melatonin and the hair follicle. J Pineal Res. 2008;44:1–15.PubMedCrossRef
66.
Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004;150:341–5.PubMedCrossRef
67.
Fischer TW, Trueb RM, Hanggi G, Innocenti M, Elsner P. Topical melatonin for treatment of androgenetic alopecia. Int J Trichol. 2012;4:236–45.CrossRef
68.
Rose PT. The latest innovations in hair transplantation. Facial Plast Surg. 2011;27:366–77.PubMedCrossRef
69.
Miao Y, Sun YB, Sun XJ, Du BJ, Jiang JD, Hu ZQ. Promotional effect of platelet-rich plasma on hair follicle reconstitution in vivo. Dermatol Surg. 2013;39:1868–76.PubMedCrossRef
70.
Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg. 2006;118(6):1458–66.
71.
Perez-Meza D, Leavitt M, Mayer M. The growth factor. Part 1: clinical and histological evaluation of the wound healing and revascularization of the hair graft after the hair transplant surgery. Hair Transpl Forum Int. 2007;17:173–5.
72.
Park KY, Kim HK, Kim BJ, Kim MN. Letter: platelet-rich plasma for treating male pattern baldness. Dermatol Surg. 2012;38:2042–4.PubMedCrossRef
73.
Takikawa M, Nakamura S, Nakamura S, et al. Enhanced effect of platelet-rich plasma containing a new carrier on hair growth. Dermatol Surg. 2011;37:1721–9.PubMedCrossRef
74.
Watanabe Y, Nagashima S, Hanzawa N. Efficacy of adenosine on male androgenetic alopecia. Jpn J Dermatol. 2005;115:57.
75.
Oura H, Iino M, Nakazawa Y, et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double-blind, randomized, placebo-controlled trial. J Dermatol. 2008;35:763–7.PubMedCrossRef
76.
Semalty M, Semalty A, Joshi GP, Rawat MS. Hair growth and rejuvenation: an overview. J Dermatol Treat. 2011;22:123–32.CrossRef
77.
Morganti P, Fabrizi G, James B, Bruno C. Effect of gelatin-cystine and serenoa repens extract on free radicals level and hair growth. J Appl Cosmetol. 1998;16:57–64.
78.
Gehring W, Gloor M. Use of the phototrichogram to assess the stimulation of hair growth—an in vivo study of women with androgenetic alopecia. Z Hautkr. 2000;75:419–23.
79.
Shao LX. Effects of the extract from bergamot and boxthorn on the delay of skin aging and hair growth in mice. Zhogguo Zhong Yao Za Zhi. 2003;28:766–9.
80.
Bussoletti C, Mastropietro F, Tolaini MV, Celleno L. Use of a cosmetic caffeine lotion in the treatment of male androgenetic alopecia. J Appl Cosmetol. 2011;29:167–80.
81.
Buonocore D, Nobile V, Michelotti A, Marzatico F. Clinical efficacy of a cosmetic treatment by Crescina(®) human follicle stem cell on healthy males with androgenetic alopecia. Dermatol Ther. 2013;3:53–62.CrossRef
82.
Kessels AG, Cardynaals RL, Borger RL, et al. The effectiveness of the hair-restorer “Dabao” in males with alopecia androgenetica. A clinical experiment. J Clin Epidemiol. 1991;44:439–47.PubMedCrossRef
83.
Kobayashi N, Suzuki R, Koide C, Suzuki T, Matsuda H, Kubo M. Effect of leaves of Ginkgo biloba on hair regrowth in C3H strain mice. Yakugaku zasshi. 1993;113:718–24.PubMed
84.
Matsuda H, Yamazaki M, Asanuma Y, Kubo M. Promotion of hair growth by ginseng radix on cultured mouse vibrissal hair follicles. Phytother Res. 2003;17:797–800.PubMedCrossRef
85.
Kim SH, Jeong KS, Ryu SY, Kim TH. Panax ginseng prevents apoptosis in hair follicles and accelerates recovery of hair medullary cells in irradiated mice. In vivo (Athens, Greece). 1998;12:219–22.
86.
Thorat RM, Jadhav VM, Kadam VJ. Development and evaluation of polyherbal formulation for hair growth-promoting activity. Int J Pharm Tech Res. 2009;1:1251–4.
87.
Kamimura A, Takahashi T, Watanabe Y. Investigation of topical application of procyanidin B-2 from apple to identify its potential use as a hair growing agent. Phytomedicine. 2000;7:529–36.PubMedCrossRef
88.
Harada N, Okajima K, Narimatsu N, Kurihara H, Nakagata N. Effect of topical application of raspberry ketone on dermal production of insulin-like growth factor-I in mice and on hair growth and skin elasticity in humans. Growth Horm IGF Res. 2008;18:335–44.PubMedCrossRef
89.
Roh SS, Kim CD, Lee MH, Hwang SL, Rang MJ, Yoon YK. The hair growth promoting effect of Sophora flavescens extract and its molecular regulation. J Dermatol Sci. 2002;30:43–9.PubMedCrossRef
90.
Camacho FM, Camacho-Serrano F, Moreno Gimenez JC, et al. Treatment of alopecias of male and female patterns. Clinical efficacy of aminexil and SP94 in two surveys of 180 patients, men and women. Medicina Cutanea Ivero-Latino-Americana. 2013;41:18–33.
91.
Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg. 2010;126:246e–8e.PubMedCrossRef
92.
Siedel U. Cimicifuga for the prevention of hair loss. Phamazeutische Zeitung. 2003;148:44.
93.
Dhanotia R, Chauhan NS, Saraf DK, Dixit VK. Effect of Citrullus colocynthis Schrad fruits on testosterone-induced alopecia. Nat Prod Res. 2011;25:1432–43.PubMedCrossRef
94.
Pumthong G, Asawanonda P, Varothai S, et al. Curcuma aeruginosa, a novel botanically derived 5alpha-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study. J Dermatol Treat. 2012;23:385–92.CrossRef
95.
Pandit S, Chauhan NS, Dixit VK. Effect of Cuscuta reflexa Roxb on androgen-induced alopecia. J Cosmet Dermatol. 2008;7:199–204.PubMedCrossRef
96.
Kwon OS, Han JH, Yoo HG, et al. Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). Phytomedicine. 2007;14:551–5.PubMedCrossRef
97.
Esfandiari A, Kelly AP. The effects of tea polyphenolic compounds on hair loss among rodents. J Natl Med Assoc. 2005;97:1165–9.PubMedCentralPubMed
98.
Pierard-Franchimont C, De Doncker P, Cauwenbergh G, Pierard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology (Basel, Switzerland). 1998;196:474–7.CrossRef
99.
Rossi A, Mari E, Scarno M, et al. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25:1167–73.PubMed
100.
Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med. 2002;8:143–52.PubMedCrossRef
101.
Floersheim GL. An examination of effect of biotin on alopecia and hair quality. Zeitschrift fur Hautkrankheiten. 1992;67:246–52.
102.
Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30:834–9.PubMedCrossRef
103.
Trachy RE, Fors TD, Pickart L, Uno H. The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Ann N Y Acad Sci. 1991;642:468–9.PubMedCrossRef
104.
Draelos ZD, Jacobson EL, Kim H, Kim M, Jacobson MK. A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. J Cosmet Dermatol. 2005;4:258–61.PubMedCrossRef
105.
Li ZJ, Choi HI, Choi DK, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012;38:1040–6.PubMedCrossRef
106.
Bunagan MJ, Banka N, Shapiro J. Hair transplantation update: procedural techniques, innovations, and applications. Dermatol Clin. 2013;31:141–53.PubMedCrossRef
107.
Kalia S, Lui H. Utilizing electromagnetic radiation for hair growth: a critical review of phototrichogenesis. Dermatol Clin. 2013;31:193–200.PubMed
108.
Gupta AD, Daigle D. The use of low level light therapy in the treatment of androgenetic alopecia and female pattern hair loss. J Dermatol Treat. 2014;25(2):162–3.
109.
Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: a randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009;29:283–92.PubMedCrossRef
110.
Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind Study. Am J Clin Dermatol. 2014;15(2):115–27.
111.
Avram MR, Leonard RT Jr, Epstein ES, Williams JL, Bauman AJ. The current role of laser/light sources in the treatment of male and female pattern hair loss. J Cosmet Laser Ther. 2007;9:27–8.PubMedCrossRef
Metadaten
Titel
Androgenetic Alopecia: An Evidence-Based Treatment Update
verfasst von
Supenya Varothai
Wilma F. Bergfeld
Publikationsdatum
01.07.2014
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 3/2014
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-014-0077-5

Weitere Artikel der Ausgabe 3/2014

American Journal of Clinical Dermatology 3/2014 Zur Ausgabe

Editorial

Evidence or Experience: That is the Question

Evidence-Based Review

Diabetic Foot Ulcer: An Evidence-Based Treatment Update

Evidence-Based Review

Mucosal Lichen Planus: An Evidence-Based Treatment Update

Evidence-Based Review

Alopecia Areata: An Evidence-Based Treatment Update

Evidence-Based Review

Systemic Therapies for Psoriasis: An Evidence-Based Update

Evidence-Based Review

Atopic Dermatitis: An Evidence-Based Treatment Update

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise